MoonLake’s nanobody boosts PsA indication hopes after Phase III success
MoonLake Immunotherapeutics said its Phase III IZAR-1 trial of sonelokimab in biologic-naive adults with active psoriatic arthritis met the primary endpoint at week 16. In the 60 mg arm, 42.1% achieved ACR50. Secondary results included ACR20 66.5%, MDA 41.2%, PASI90 61%. Patients will be followed 52 weeks, with durability data expected in H1 2027. MoonLake is also running IZAR-2 versus AbbVie’s Skyrizi.
How this was made
The 30-second read
Why it matters
The IZAR-1 Phase III topline provides concrete efficacy percentages across multiple endpoints at week 16 and sets up a longer durability readout, which can shift approval probability and valuation expectations.
Market read
Traders can reassess probability-weighted PsA approval and competitive positioning based on the reported ACR50/ACR20, MDA, and PASI90 outcomes, while monitoring the later durability and HS catalysts.
What to watch
The article highlights durability data only expected in H1 2027 and does not quantify safety/tolerability or effect size versus active comparators, which could limit how much the market reprices today.
Background
MoonLake is developing sonelokimab (nanobody) for psoriatic arthritis, with additional programs in hidradenitis suppurativa (HS).
Ticker impact
MoonLake’s Phase III IZAR-1 for sonelokimab in psoriatic arthritis met its primary endpoint at week 16 with 42.1% ACR50.
Likely supports upside bias versus pre-news levels, with volatility around follow-on durability data in H1 2027 and competitive positioning.
The article provides specific IZAR-1 efficacy rates and notes continued treatment for 52 weeks, but it does not include regulatory filings, guidance, or a new competitive outcome beyond the topline.
Market effects
Reinforces IL-17A/F class efficacy in PsA, potentially raising competitive expectations for other late-stage programs.
No specific regional demand or regulatory signal beyond global PsA market growth estimates.
Competitive read-through for multinational biologics developers targeting PsA and related inflammatory indications.
Counterpoint
Despite meeting endpoints, investors may discount topline if durability, safety, or differentiation versus established competitors (e.g., bimekizumab, risankizumab) is not clearly superior.
Key entities
- companyMoonLake Immunotherapeutics
Nasdaq-listed developer of sonelokimab; reported IZAR-1 Phase III topline success in PsA.
- drugsonelokimab
MoonLake’s nanobody targeting IL-17A/F; met primary and key secondary endpoints in PsA Phase III IZAR-1.
- clinical_trialIZAR-1 (NCT06641076)
Phase III trial in biologic-naive adults with active PsA; primary endpoint met at week 16.
- clinical_trialIZAR-2 (NCT06641089)
Phase III trial adding a standard-of-care arm versus AbbVie’s Skyrizi in anti-TNFa inadequate responders.
- companyUCB
Mentioned via its PsA drug Bimzelx as a competitive benchmark.
